Effectiveness of the recombinant zoster vaccine in adult patients with multiple sclerosis: A claims-based retrospective cohort study in the United States.

Sheryl A Kluberg¹, Sophie E Mayer¹, O'Mareen Spence², Driss Oraichi², Harry Seifert², Omar Ali², Huifeng Yun², Andrew L Simon³, Jenice S Ko³, Caroline Hugh³, Meg Her³, Kathleen Shattuck³, Aziza Jamal-Allial⁴, Djeneba Audrey Djibo⁵, Kimberly Daniels⁶, Qianli Ma⁷, Cheryl N McMahill-Walraven⁸, Rachel P Ogilvie⁹, Kristin Palmsten¹⁰, Mano Selvan⁷, Najat J Ziyadeh⁹, Shamik Bhattacharyya¹¹, Alexis Ogdie¹², Michael George¹²

¹Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA.

²GSK, Rockville, MD, USA.

³Department of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, MA, USA.

⁴Carelon Research, Wilmington, DE, USA; Fakeeh Care Group, Jeddah, Saudi Arabia.

⁵CVS Health, Blue Bell, PA, USA.

⁶Carelon Research, Wilmington, DE, USA.

⁷Humana Healthcare Research, Inc., Louisville, KY, USA.

⁸CVS Health, Blue Bell, PA, USA; Glade Oak, Inc., Royersford, PA, USA.

⁹Optum, Boston, MA, USA.

¹⁰HealthPartners Institute, Bloomington, MN, USA.

¹¹Mass General Brigham, Boston, MA, USA.

¹²Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA, USA.

PubMed DOI

Abstract

OBJECTIVES: To assess vaccine effectiveness (VE) of the recombinant zoster vaccine (RZV) in adults with multiple sclerosis (MS). METHODS: This retrospective study included adults aged ⩾18 years with MS insured by Medicare or one of seven United States (US) commercial health insurers from January 2018 to September 2023. Adults receiving two RZV doses ⩾28 days apart were matched with four or less u…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.